BE1001263A4 - Procede en vue de provoquer la regression de la leucemie et l'inhibition de la croissance des tumeurs chez les mammiferes. - Google Patents

Procede en vue de provoquer la regression de la leucemie et l'inhibition de la croissance des tumeurs chez les mammiferes. Download PDF

Info

Publication number
BE1001263A4
BE1001263A4 BE8800818A BE8800818A BE1001263A4 BE 1001263 A4 BE1001263 A4 BE 1001263A4 BE 8800818 A BE8800818 A BE 8800818A BE 8800818 A BE8800818 A BE 8800818A BE 1001263 A4 BE1001263 A4 BE 1001263A4
Authority
BE
Belgium
Prior art keywords
pyrimidine
compound
fluorophenyl
carboxamide
hydroxy
Prior art date
Application number
BE8800818A
Other languages
English (en)
French (fr)
Inventor
Arthur D Brewer
Original Assignee
Uniroyal Chem Co Inc
Uniroyal Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR8803462A priority Critical patent/FR2628869A1/fr
Priority to GB8815055A priority patent/GB2219999A/en
Application filed by Uniroyal Chem Co Inc, Uniroyal Chemical Ltd filed Critical Uniroyal Chem Co Inc
Priority to BE8800818A priority patent/BE1001263A4/fr
Application granted granted Critical
Publication of BE1001263A4 publication Critical patent/BE1001263A4/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BE8800818A 1988-07-14 1988-07-14 Procede en vue de provoquer la regression de la leucemie et l'inhibition de la croissance des tumeurs chez les mammiferes. BE1001263A4 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
FR8803462A FR2628869A1 (zh) 1988-07-14 1988-03-17
GB8815055A GB2219999A (en) 1988-07-14 1988-06-24 Substituted 5-pyrimidinecarboxamides and treatment of leukemia
BE8800818A BE1001263A4 (fr) 1988-07-14 1988-07-14 Procede en vue de provoquer la regression de la leucemie et l'inhibition de la croissance des tumeurs chez les mammiferes.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BE8800818A BE1001263A4 (fr) 1988-07-14 1988-07-14 Procede en vue de provoquer la regression de la leucemie et l'inhibition de la croissance des tumeurs chez les mammiferes.

Publications (1)

Publication Number Publication Date
BE1001263A4 true BE1001263A4 (fr) 1989-09-05

Family

ID=3883532

Family Applications (1)

Application Number Title Priority Date Filing Date
BE8800818A BE1001263A4 (fr) 1988-07-14 1988-07-14 Procede en vue de provoquer la regression de la leucemie et l'inhibition de la croissance des tumeurs chez les mammiferes.

Country Status (3)

Country Link
BE (1) BE1001263A4 (zh)
FR (1) FR2628869A1 (zh)
GB (1) GB2219999A (zh)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2174391A (en) * 1985-04-22 1986-11-05 Uniroyal Chem Co Inc 5-pyrimidinecarboxamides and treatment of leukemia and tumours therewith

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2174391A (en) * 1985-04-22 1986-11-05 Uniroyal Chem Co Inc 5-pyrimidinecarboxamides and treatment of leukemia and tumours therewith

Also Published As

Publication number Publication date
FR2628869A1 (zh) 1989-09-22
GB8815055D0 (en) 1988-08-03
GB2219999A (en) 1989-12-28

Similar Documents

Publication Publication Date Title
EP0593601B1 (fr) Nouvelles compositions a base de derives de la classe des taxanes
FR2577551A1 (fr) Derives de benzoyl uree, procede pour les preparer, et compositions antitumorales les contenant
FR2580642A1 (fr) 5-pyrimidinecarboxamides et traitement de la leucemie et des tumeurs en les utilisant
FR2524314A1 (fr) Medicament a action salidiuretique, contenant des dihydropyridines
LU86484A1 (fr) Sels de furosemide
BE1003632A3 (fr) Nouveaux derives de l'adenosine, leur preparation et leur utilisation comme medicaments.
CA2902276A1 (fr) Heterocycles phosphores analogues de sucres a activite antimetastatique
BE1001263A4 (fr) Procede en vue de provoquer la regression de la leucemie et l'inhibition de la croissance des tumeurs chez les mammiferes.
BE1004551A3 (fr) Derives n-imidazolyliques de composes bicycliques, interessants dans le domaine medical.
EP1358159B1 (fr) Tartrate et phosphate de 3,4-diaminopyridine, compositions pharmaceutiques et utilisations
CA2064999A1 (fr) Derives de la 5-amino-1,2,3,4 tetrahydro-acridine et utilisation comme medicaments
EP0412901A2 (fr) Utilisation de trifluorométhyl-phényltétrahydropyridines pour la préparation de médicaments destinés à combattre les troubles de la motricité intestinale
BE1001262A4 (fr) Procede en vue de provoquer la regression de la leucemie et l'inhibition de la croissance des tumeurs chez les mammiferes.
LU87275A1 (fr) Procede en vue de provoquer la regression de la leucemie et l'inhibition de la croissance des tumeurs chez les mammiferes
LU87152A1 (fr) 3-(2-haloalkyl)-1,4-oxathiines et 2-(2-haloalkyl)-1,4-dithiines,de meme que le traitement de la leucemie et des tumeurs avec ces substances
EP0718289A1 (en) Novel parabanic acid derivatives as aldose reductase inhibitors
EP0161249A1 (fr) Enamides acyles et compositions pharmaceutiques les contenant
LU87274A1 (fr) Procede en vue de provoquer la regression de la leucemie et l'inhibition de la croissance des tumeurs chez les mammiferes
EP0986390B1 (fr) Compositions pharmaceutiques contenant du dichlorhydrate de cinchonine
CH641775A5 (fr) N-(1-methyl 2-pyrrolidinyl methyl) 2,3-dimethoxy 5-methylsulfamoyl benzamide et ses derives, son procede de preparation et composition le renferment.
CA1263391A (fr) N-carboxyalcoyl-2 oxo-3 diaryl 5-6 triazines utiles en therapeutique
KR100847565B1 (ko) 디아세트아미도콜히친 및/또는 디아세트아미도디히드로티오콜히친을 함유하는 약제학적 조성물 및 이들 화합물의 제조방법
FR2516085A1 (fr) Sels quaternaires de n,n3-di(b-bromopropionyl)-n1,n2-dispirotripiperazinium, procede de preparation desdits sels et medicament a action antitumorale a base d'un tel sel
CH622251A5 (zh)
FR2672894A1 (fr) Composes de phosphines a noyau heterocyclique constitue de carbone, oxygene, azote et utilise dans des compositions pharmaceutiques.

Legal Events

Date Code Title Description
RE Patent lapsed

Owner name: UNIROYAL CHEMICAL LTD/UNIROYAL CHEMICAL LTEE

Effective date: 19900731

Owner name: UNIROYAL CHEMICAL INC.

Effective date: 19900731